Phylogica Limited (ASX: PYC) set to reach experimental milestone

KEY TAKEAWAYS:

• Phylogica Limited (ASX: PYC) is expected to complete their experience of delivering Cre Cargo into the nucleus cells in multiple tissues in live animals.
• The success of the delivery will represent a significant milestone for the company, transitioning them from proof of concept to therapeutic cargoes.

Phylogica (ASX: PYC) has announced that their experimental timelines are on track. The company will deliver the Cre cargo (enzyme) into the nucleus cells in multiple tissues in a live animal in July 2018. Phylogica’s core asset is their structurally diverse drug library which the company has chosen to use in identifying Cell Penetrating Peptides (CPPs). The successful delivery of the Cre cargo in the animal experiments will be a significant milestone for the company and help with the commercial validation of the company’s biological peptides. It will enable the transition for proof of concept stage of validating their platform to the testing of therapeutic drug cargoes.

The company has an opportunity to improve their attractiveness of the platform by delivering a cargo class of interest into a target cell more efficiently than competitive technology. The company’s original CPP has already successfully delivered Cre into kidney cells. The company has also commenced further screening of their re-populated libraries to identify additional CPPs and has gained strong interest from biotech companies who are looking for effective delivery platforms for their developed drug cargoes.

About Phylogica Limited (ASX: PYC)

Phylogica’s drug delivery platform harnesses the power of viruses and bacteria for good. These organisms have long been known to cross the cell wall to where the highest value drug targets reside. Phylogica’s delivery technology uses their genetic secrets to take drug cargoes where they cannot go alone – unlocking the undruggable genome.

Request Info